Retatrutide Prescribed Online to New York Residents
Medical Weight Loss Treatment in New York
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving New York
New York is a world unto itself—from the skyscrapers of Manhattan to the farms of the Finger Lakes, the tech corridors of the Hudson Valley to the winter sports meccas of the Adirondacks. OmniRx Health serves every New Yorker. Whether you're a Wall Street professional who can't take time off, an upstate family far from specialists, or an artist in Brooklyn seeking convenient care, our telehealth platform delivers Empire State-quality medicine to wherever you are.
OmniRx Health providers are licensed by the New York State Education Department to deliver telehealth across the Empire State.
New York's vast pharmacy network from NYC to Buffalo ensures prescription access, with specialized compounding pharmacies available throughout.
New York has comprehensive telehealth laws that support virtual care delivery across the state's diverse urban and rural communities.
New York mandates telehealth coverage, including requirements for commercial insurers and Medicaid to cover virtual visits.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in New York?
- Yes, New York has comprehensive telehealth laws supporting virtual healthcare. The state expanded virtual care access permanently, ensuring residents can access quality telehealth services.
- Can NYC residents use telehealth despite nearby doctors?
- Absolutely. Telehealth saves busy New Yorkers time by eliminating travel and waiting rooms. Get the same quality care from your apartment, office, or wherever you are.
- Does NY Medicaid cover telehealth?
- Yes, New York Medicaid covers telehealth services for eligible members. The state has made permanent many telehealth flexibilities that improve access to care.